Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v24.i5.20
pages 445-492

Optimizing Drug Delivery for Enhancing Therapeutic Efficacy of Recombinant Human Endostatin in Cancer Treatment

Fuguo Xu
Department of Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
Qingyong Ma
Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China
Huanchen Sha
Department of Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China


Recombinant human endostatin (rhEndostatin) is uniquely able to target neovascular endothelial cells (ECs) and has the potential for antiangiogenetic and antitumor activities. In this review, we explore experimental approaches and clinical trials focusing on drug delivery of endostatin. Continued endostatin therapy can maintain tumors in a state of dormancy, and no signs of drug-induced resistance have been observed. Prolonged delivery of endostatin may be achieved by using pumps (mini-osmotic pumps) or cell encapsulation systems. The largest benefit from rhEndostatin is expected when drug delivery of rhEndostatin is begun as early as possible. Although endostatin has shown promise in controlling tumor neovasculature, a major problem in pharmacotherapy is the side effects of constant drug administration and the limited half-life of antiangiogenic proteins. Gene therapy offers the advantages of maximizing cost effectiveness and maintaining sustained levels of antiangiogenic factors, which may enhance antitumor efficacy. Therefore, we have investigated recent advances in gene delivery of endostatin for cancer treatment. In recent years, preclinical and clinical data have demonstrated the synergistic effects of rhEndostatin combined with other therapies on inhibiting growth of malignant tumors, with minimal toxicity. rhEndostatin has not been proven to prolong the survival rate of patients challenged with cancer when used as single therapy. Thus, we suggest that the combination of rhEndostatin with chemotherapy, radiotherapy, and biotherapy (i.e., fusion protein, molecular-targeted therapy on cancers, etc.) might provide an optimal strategy for cancer treatment.

Articles with similar content:

Immunocytokines for Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
Dario Neri, Philipp Probst
Novel Approaches for Colon Cancer Prevention by Cyclooxygenase-2 Inhibitors
Journal of Environmental Pathology, Toxicology and Oncology, Vol.21, 2002, issue 2
Bandaru S. Reddy, Chinthalapally V. Rao
An Update on Angiogenesis Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.11, 2001, issue 1-3
Vinod Labhasetwar, Jasmine Davda
Individual Response to Ionizing Radiation and Personalized Radiotherapy
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 1-2
Alex Philchenkov, Anna Dubrovska, Emiliya A. Domina
Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 2
Vivek Ranjan Sinha, Honey